Overnutrition  >>  Symlin (pramlintide)  >>  Phase 2
Welcome,         Profile    Billing    Logout  

4 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Symlin (pramlintide) / AstraZeneca
NCT00112021: A Study to Examine the Effect of Pramlintide on Body Weight and Its Safety and Tolerability in Obese Subjects

Completed
2b
400
US
pramlintide acetate, Pramlintide acetate injection (Pramlintide (0.6 mg/mL)) is a clear, colorless, sterile solution for SC injection
AstraZeneca
Obesity
11/05
11/05
NCT00189514: A Study to Examine the Long Term Effect of Pramlintide on Body Weight and Its Safety and Tolerability in Obese Subjects

Completed
2
210
US
pramlintide acetate, Symlin, placebo
AstraZeneca
Obesity
06/07
06/07
NCT00402077: A Study to Examine the Safety, Tolerability, and Body Weight Effect of Pramlintide Alone and in Combination With Oral Antiobesity Agents in Overweight and Obese Subjects

Completed
2
258
US
pramlintide acetate, Symlin, sibutramine, Meridia, phentermine, Adipex-P, Fastin, Obenix, Oby-Trim, placebo
AstraZeneca
Overweight, Obesity
08/07
08/07
NCT00673387: Study to Examine Safety, Tolerability, and Effect on Body Weight of Metreleptin Administered in Conjunction With Pramlintide in Obese and Overweight Subjects

Completed
2
636
US
pramlintide acetate, Smylin, metreleptin, placebo-P, Placebo matched to pramlintide, placebo-M, Placebo matched to Metreleptin
AstraZeneca
Overweight, Obesity
04/09
10/09

Download Options